Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with HCV genotype 2 or 3~* Cirrhosis determination~* Subject meets one of the following classifications:~  1. IFN unwilling~ 2. IFN ineligible~ 3. IFN intolerant~* Screening laboratory values within defined thresholds~* Subject has not been treated with any investigational drug or device within 30 days of the Screening visit~* Use of highly effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase~* Pregnant or nursing female or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~* Excessive alcohol ingestion or significant drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV (Type: EXPERIMENTAL): Participants were randomized to receive SOF+RBV for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).